Expert Underscores Importance of AE Management in GU Cancers

May 9, 2018 – Although they tend to be less common, adverse event (AE) management is still imperative with immunotherapies and requires a multidisciplinary approach, says Xiao X. Wei, MD, MAS. While revisions to the ASCO, NCCN, and ESMO guidelines have given clinicians a better understanding of how to manage immune-related AEs, the adjustments have not eliminated the need for individualized treatment of patients with genitourinary (GU) cancers. “There are no … (leggi tutto)